Rocket Pharmaceuticals, Inc. financials

RCKT CIK 0001281895

Source: EDGAR filings · Built 2026-06-02T03:55:02Z

Custom taxonomy namespace: ffd

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow -192.31M -217.38M -212.65M -188.19M -130.43M -96.32M
EBITDA -222.85M -266.00M -254.76M -220.44M -164.05M -133.16M
Working Capital 162.53M 337.50M 329.72M 324.89M 369.89M 454.73M
Net Debt -52.68M -138.14M -30.86M -117.65M -210.09M -235.40M
Return on Equity (ROE) -80.49% -55.86% -49.86% -45.31% -37.18% -27.74%
Return on Assets (ROA) -67.52% -49.03% -43.37% -40.21% -34.02% -23.64%
Current Ratio 6.38× 9.30× 7.80× 9.29× 17.69× 14.94×
Debt-to-Equity 0.09× 0.06× 0.05× 0.05× 0.05× 0.12×
Effective Tax Rate 0.00% 0.00%
Cash Conversion Ratio 0.85× 0.81× 0.79× 0.80× 0.72× 0.53×
Accruals Ratio -0.10× -0.09× -0.09× -0.08× -0.10× -0.11×
CapEx Coverage -82.76× -27.40× -10.99× -17.73× -13.08× -3.44×
Free Cash Flow Per Share $-1.73 $-2.29 $-2.53 $-2.76 $-2.06 $-1.74

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
P/B 1.37× 2.89× 5.49× 3.16× 3.10× 6.64×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenue from Contract with Customer, Excluding Assessed Tax 0 0 0 0 0 0
Research and Development Expense 142.01M 171.24M 186.34M 165.57M 125.48M 105.44M
Operating Expenses 231.75M 273.20M 259.66M 224.34M 167.25M 134.30M
Operating Income (Loss) -231.75M -273.20M -259.66M -224.34M -167.25M -134.30M
Income Tax Expense (Benefit) 0 0 0
Net Income (Loss) Attributable to Parent -223.12M -258.75M -245.59M -221.86M -169.07M -139.70M
Earnings Per Share, Basic $-2.01 $-2.73 $-2.92 $-3.26 $-2.67 $-2.52
Weighted Average Number of Shares Outstanding, Basic 111.12M 94.81M 84.01M 68.15M 63.24M 55.38M
Earnings Per Share, Diluted $-2.01 $-2.73 $-2.92 $-3.26 $-2.67 $-2.52
Weighted Average Number of Shares Outstanding, Diluted 111.12M 94.81M 84.01M 68.15M 63.24M 55.38M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 77.56M 163.63M 55.90M 140.52M 232.69M 297.10M
Assets, Current 192.73M 378.18M 378.22M 364.06M 392.06M 487.35M
Assets 330.45M 527.70M 566.34M 551.81M 497.02M 590.82M
Liabilities, Current 30.21M 40.68M 48.51M 39.17M 22.17M 32.62M
Liabilities 53.23M 64.47M 73.77M 62.12M 42.30M 87.31M
Stockholders' Equity Attributable to Parent 277.22M 463.23M 492.57M 489.69M 454.72M 503.52M
Common Stock, Shares, Outstanding 108.32M 106.45M 90.28M 79.12M 64.51M 61.00M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities -190.01M -209.72M -194.92M -178.14M -121.16M -74.64M
Payments to Acquire Property, Plant, and Equipment 440.00K 5.86M 16.44M 8.36M 7.62M 20.61M
Net Cash Provided by (Used in) Investing Activities 103.77M 131.71M -98.07M -69.33M 18.85M -96.59M
Payments for Repurchase of Common Stock 0 72.00K
Net Cash Provided by (Used in) Financing Activities 148.00K 185.74M 208.40M 155.29M 37.68M 282.99M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (RCKT CIK 0001281895), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

WERN

WERNER ENTERPRISES, INC.

EGBN

Eagle Bancorp, Inc.

NPK

National Presto Industries, Inc.